Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $108
Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $108
Barrington Research 維持對美國血液技術的強烈推薦，將價格目標上調至108美元。
Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $107 to $108.
Barrington Research分析師Michael Petusky維持Haemonetics (紐交所:HAE)爲強於大市表現評級，將目標股價從107美元升至108美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。